Tarsus Pharmaceuticals, Inc.
Financials
Valuation Metrics
Tarsus Pharmaceuticals, Inc.'s Market Cap is $3.16B. At end of 2025 it was $3.50B. Ranked #1653 of 3,118 in US market (top 53%), #584 of 1,474 on NASDAQ (top 40%), #97 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 37%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.16B | US#1,653/3,118 Sec#97/265 |
| Revenue | $606M | US#2,155/3,118 Sec#72/265 |
| Net Income | $-46M | US—/3,118 Sec—/265 |
| Total Assets | $611M | US#2,687/3,118 Sec#140/265 |
| Net Assets | $347M | US#2,446/3,118 Sec#148/265 |
| Employees | 370 | US#2,351/3,118 Sec#100/265 |
| Value | ||
| P/B | 9.11x | US#2,588/3,118 Sec#190/265 |
| P/S | 5.21x | US#2,348/3,118 Sec#83/265 |
| FCF Yield | 1.95% | US#2,035/3,118 Sec#68/265 |
| Profitability | ||
| ROE | -13.40% | US#2,405/3,118 Sec#88/265 |
| ROA | -7.60% | US#2,602/3,118 Sec#95/265 |
| Op. Margin | -8.00% | US#2,495/3,118 Sec#93/265 |
| Revenue Growth | 105.17% | US#88/3,118 Sec#31/265 |
| Financial Health | ||
| Debt Ratio | 76.26% | US#840/3,118 Sec#151/265 |
| Total Debt | $89M | US#2,460/3,118 Sec#127/265 |
| FCF | $62M | US#1,896/3,118 Sec#67/265 |
| Cash | $205M | US#1,713/3,118 Sec#106/265 |
| Current Ratio | 3.20x | US#718/3,118 Sec#181/265 |
| Performance | ||
| 1Y Return | 6.66% | US#1,538/3,118 Sec#132/265 |
| 1M Return | 0.53% | US#2,174/3,118 Sec#152/265 |
| From 52W High | -19.82% | US#1,375/3,118 Sec#73/265 |
| 1Y MDD | -32.00% | US#1,442/3,118 Sec#74/265 |
| Trading | ||
| Volume | 319,971 shares | US#2,337/3,118 Sec#223/265 |
| Trading Value | $24M | US#1,747/3,118 Sec#126/265 |
| Per Share | ||
| EPS | $-1.08 | US—/3,118 Sec—/265 |
| BPS | $8.06 | US#1,993/3,118 Sec#87/265 |
Company Info
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.